News headlines about Express Scripts (NASDAQ:ESRX) have trended somewhat positive on Saturday, Accern reports. The research group identifies positive and negative press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Express Scripts earned a news impact score of 0.19 on Accern’s scale. Accern also gave headlines about the company an impact score of 45.7115245063099 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
These are some of the headlines that may have effected Accern’s scoring:
- Express Scripts Holding Company — Moody’s changes direction of Express Scripts rating review from uncertain to downgrade (finance.yahoo.com)
- Carl Icahn dials down his opposition to Cigna-Express Scripts deal (marketwatch.com)
- Report : CVS-Aetna, Cigna-Express Scripts Mergers Close To Justice Dept Approval (markets.businessinsider.com)
- Major Health-Industry Deals Move Closer to Approval (finance.yahoo.com)
- Express Scripts Holding Co (ESRX) Receives Consensus Rating of “Hold” from Analysts (americanbankingnews.com)
A number of equities analysts have commented on ESRX shares. BidaskClub upgraded Express Scripts from a “hold” rating to a “buy” rating in a research note on Tuesday, May 22nd. Zacks Investment Research upgraded Express Scripts from a “strong sell” rating to a “hold” rating in a research note on Tuesday, June 26th. Royal Bank of Canada raised their price objective on Express Scripts to $94.00 and gave the stock an “outperform” rating in a research note on Monday, August 27th. Robert W. Baird set a $92.00 price objective on Express Scripts and gave the stock a “buy” rating in a research note on Thursday, May 17th. Finally, William Blair upgraded Express Scripts from a “market perform” rating to an “outperform” rating in a research note on Wednesday, August 1st. Three analysts have rated the stock with a sell rating, thirteen have given a hold rating and four have issued a buy rating to the stock. Express Scripts currently has an average rating of “Hold” and a consensus price target of $85.58.
Express Scripts stock opened at $90.80 on Friday. Express Scripts has a one year low of $55.80 and a one year high of $91.03. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.59 and a current ratio of 0.71. The firm has a market cap of $50.50 billion, a price-to-earnings ratio of 12.79, a P/E/G ratio of 1.13 and a beta of 1.00.
Express Scripts (NASDAQ:ESRX) last issued its earnings results on Wednesday, August 1st. The company reported $2.22 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.20 by $0.02. The firm had revenue of $25.64 billion for the quarter, compared to the consensus estimate of $25.43 billion. Express Scripts had a return on equity of 25.49% and a net margin of 4.65%. The company’s revenue was up 1.2% compared to the same quarter last year. During the same quarter last year, the business posted $1.73 EPS. equities research analysts expect that Express Scripts will post 9.07 earnings per share for the current fiscal year.
In other Express Scripts news, insider Christine Houston sold 10,000 shares of the firm’s stock in a transaction on Wednesday, June 13th. The stock was sold at an average price of $82.28, for a total value of $822,800.00. Following the sale, the insider now owns 108,010 shares of the company’s stock, valued at approximately $8,887,062.80. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 0.79% of the company’s stock.
Express Scripts Company Profile
Express Scripts Holding Company operates as a pharmacy benefit management (PBM) company in the United States and Canada. The company's PBM segment offers clinical solutions; and specialized pharmacy care, home delivery and specialty pharmacy, retail network pharmacy administration, benefit design consultation, drug utilization review, drug formulary management, public exchange, administration of group purchasing organization, and digital consumer health and drug information services.
Featured Story: How to Invest in an Index Fund
Receive News & Ratings for Express Scripts Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Express Scripts and related companies with MarketBeat.com's FREE daily email newsletter.